Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Mizuho analyst Salim Syed initiated coverage on Maze Therapeutics Inc (NASDAQ:MAZE) with an Outperform rating and announced a price target of $97. Maze Therapeutics shares closed at $45.06 on Monday. See how other analysts view this stock.
- B. Riley Securities analyst Fedor Shabalin initiated coverage on Strategy Inc (NASDAQ:MSTR) with a Buy rating and announced a price target of $175. Strategy shares closed at $138.95 on Monday. See how other analysts view this stock.
- Rodman & Renshaw analyst Michael King initiated coverage on Karyopharm Therapeutics Inc (NASDAQ:KPTI) with a Buy rating and announced a price target of $28. Karyopharm Therapeutics shares closed at $8.49 on Monday. See how other analysts view this stock.
- Roth Capital analyst Boobalan Pachaiyappan initiated coverage on Neurosense Therapeutics Ltd (NASDAQ:NRSN) with a Buy rating and announced a price target of $3. NeuroSense Therapeutics shares closed at $0.84 on Monday. See how other analysts view this stock.
- BTIG analyst Janine Stichter initiated coverage on Crocs Inc (NASDAQ:CROX) with a Neutral rating. Crocs shares closed at $87.16 on Monday. See how other analysts view this stock.
Considering buying MSTR stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments